Aspira Women's Health

company

About

Aspira Women's Health develops and commercializes diagnostic tests that address unmet needs in gynecologic oncology and women’s health.

  • 101 - 250

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$10.50M
Industries
Biotechnology,Health Care,Health Diagnostics,Women's
Founded date
Jan 1, 1993
Number Of Employee
101 - 250
Operating Status
Active

Aspira Women's Health develops and commercializes high-value, multi-marker, diagnostic tests that address unmet needs in gynecologic oncology and women’s health. The company is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.

Its OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. They focus on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.

Aspira Women's Health was founded in 1993 and is headquartered in Austin, Texas, USA.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$10.50M
Aspira Women's Health has raised a total of $10.50M in funding over 2 rounds. Their latest funding was raised on Dec 23, 2014 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 23, 2014 Post-IPO Equity $10.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Aspira Women's Health is funded by 1 investors. Birchview Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Birchview Fund Post-IPO Equity